You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 132 No. 7, July 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (4)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Neoplasms of Head & Neck
 •Salivary Gland Disorders
 •Alert me on articles by topic

Metastasizing Pleomorphic Salivary Adenoma

S. A. R. Nouraei, MBBChir; M. S. Ferguson, MRCS; P. M. Clarke, FRCS; A. Sandison, FRCPath; G. S. Sandhu, FRCS; L. Michaels, FRCPath; P. Rhys-Evans, FRCS

Arch Otolaryngol Head Neck Surg. 2006;132:788-793.

Objective  To address questions about the etiology, behavior, optimal treatment, and prognosis of metastasizing pleomorphic adenoma (MPA), we undertook a review of the literature (1953-2005) and constructed a virtual series of all identified cases of MPA, metastatic lesions that are very occasionally identified in patients with a history of pleomorphic salivary adenoma and, on detailed pathological evaluation, found to exhibit all the histological hallmarks of the preceding benign lesions.

Data Sources  A review of the English-language literature between 1953 and 2005 using MEDLINE, secondary references identified from bibliographies of pertinent articles, and a further case from one of our institutions.

Data Synthesis  A virtual case series was constructed and quantitatively analyzed. Forty-two patients with an average age of 33 years were identified. There were 20 male and 22 female patients. There was an overwhelming history of incomplete surgery for pleomorphic salivary adenoma. Most patients had locoregional recurrences before metastasis, and the mean presentation-to-metastasis latency was 16 years. Bone was the most common site for metastases (45%), followed by the head and neck (43%) and lung (36%). There was significant morbidity and mortality from distant disease, with 5-year disease-specific and disease-free survival of 58% and 50%, respectively. Developing distant lesions within 10 years of the primary tumor and presence of metastases in multiple sites were independent predictors of survival on Cox regression analysis. Metastasectomy conferred significant survival advantage over nonoperative treatment (log-rank analysis, P<.02). Chemotherapy and radiotherapy were of limited value.

Conclusions  Meticulous surgery is crucial in preventing MPA. Metastatic disease carries significant morbidity and mortality and should be treated surgically when feasible.


Author Affiliations: Departments of Otolaryngology–Head and Neck Surgery (Drs Nouraei, Clarke, and Sandhu) and Histopathology (Drs Sandison and Michaels), Charing Cross Hospital, London, England; Department of Paediatric Surgery, Great Ormond Street Hospital for Sick Children, London (Dr Ferguson); and Department of Head & Neck Surgery, Royal Marsden Hospital, London (Drs Clarke and Rhys-Evans). Dr Ferguson is now with the Department of Otolaryngology–Head and Neck Surgery, Barts and the London Hospital, London.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.